MarketPeel
Insider Trading Intelligence
JC

Jason Cavalier

LYRA
CHIEF FINANCIAL OFFICER · LYRA THERAPEUTICS, INC. · CIK 0001883290
FILING MIX · LIFETIME75%/25%
BUYS
6
SELLS
2
TOTAL VALUE
$8.7K
COMPANIES
1
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
518,547
AVG SELL PX
$5.97
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Jason Cavalier, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-23.20%+0.32%-23.52%-23.52%
14d2+100.00%-20.26%-0.34%-19.91%-19.91%
30d2+100.00%-36.69%-0.12%-36.57%-36.57%
60d2+100.00%-44.55%+0.43%-44.99%-44.99%
90d2+100.00%-50.10%+1.40%-51.50%-51.50%
180d2(1 pending)+100.00%-62.91%+10.54%-73.46%-73.46%
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LYRA · 518,547 shares · as of Jan 6, 2026
0130,000260,000390,000520,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 6 buys / 2 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LYRA
LYRA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
769$3.36$2.6K518,547Jan 6, 2026Jan 8, 2026View →
LYRA
LYRA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
684$8.91$6.1K519,316Jul 10, 2025Jul 14, 2025View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
420,000520,000Jan 8, 2025Jan 10, 2025View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Oct 16, 2024Oct 18, 2024View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jan 30, 2024Feb 1, 2024View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
140,000140,000Jan 31, 2023Feb 2, 2023View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,60515,605Feb 12, 2022Feb 15, 2022View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
104,000104,000Sep 13, 2021Sep 15, 2021View →
Other insiders · LYRA
Loading peer insiders…
About this filer
CIK 0001883290
ROLE
Chief Financial Officer
PRIMARY
LYRA
COMPANIES
1
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001883290DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback